Elicio Therapeutics Inc. - Asset Resilience Ratio

Latest as of March 2022: 22.84%

Elicio Therapeutics Inc. (ELTX) has an Asset Resilience Ratio of 22.84% as of March 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ELTX total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

$18.56 Million

Cash + Short-term Investments

Total Assets

$81.26 Million

All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Elicio Therapeutics Inc.'s Asset Resilience Ratio has changed over time. See Elicio Therapeutics Inc. net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Elicio Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Elicio Therapeutics Inc. (ELTX) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$18.56 Million	22.84%
Total Liquid Assets	$18.56 Million	22.84%

Asset Resilience Insights

Good Liquidity Position: Elicio Therapeutics Inc. maintains a healthy 22.84% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Elicio Therapeutics Inc. Industry Peers by Asset Resilience Ratio

Compare Elicio Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for Elicio Therapeutics Inc. (None–None)

The table below shows the annual Asset Resilience Ratio data for Elicio Therapeutics Inc..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
No yearly data available.

pp = percentage points

About Elicio Therapeutics Inc.

NASDAQ:ELTX USA Biotechnology

Market Cap

$197.76 Million

Market Cap Rank

#16748 Global

#3787 in USA

Share Price

$10.75

Change (1 day)

+1.22%

52-Week Range

$4.96 - $13.84

All Time High

$257.40